Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,448 matching trials from the live ClinicalTrials.gov search.
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Semaglutide, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Conditions
Heart Failure
Interventions
THRV-1268, Placebo
Drug
Lead sponsor
Thryv Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
Interventions
MYK-461
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 4 more
Conditions
Preterm Premature Rupture of Membrane
Interventions
Azithromycin 500 mg, Azithromycin Oral Product
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
14 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

The Evaluation of Belimumab in Myasthenia Gravis (MG)

NCT01480596
Conditions
Myasthaenia Gravis
Interventions
Belimumab, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 12 more
Conditions
Obesity
Interventions
BMS-830216, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
5
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 2 more
Conditions
Polycythemia Vera
Interventions
XL019
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 2 more
Conditions
Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Interventions
MT-3724, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Orange, California • Santa Monica, California • Whittier, California + 6 more
Conditions
Kidney Stones
Interventions
LLX-424
Drug
Lead sponsor
Lilac Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Saint Paul, Minnesota • Springfield, Missouri • San Antonio, Texas
Conditions
Alzheimer's Disease
Interventions
ABBV-1758, Placebo for ABBV-1758
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Irvine, California • Boulder, Colorado • Bradenton, Florida + 8 more
Conditions
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
ACE-232 tablets
Drug
Lead sponsor
Acerand Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Glycine Pharmacodynamic Study

NCT01610011
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Glycine administration
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Heart Failure, ADHF, Chronic Heart Failure, CHF
Interventions
Cenderitide, Placebo
Drug · Other
Lead sponsor
Nile Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Tustin, California • Jacksonville, Florida • Lenexa, Kansas + 2 more
Conditions
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Interventions
AAV1/SERCA2a
Biological
Lead sponsor
Sardocor Corp.
Industry
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Conditions
Atherosclerosis
Interventions
Darapladib (SB480848)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Interventions
Administration of AZD6738
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
La Jolla, California
Conditions
Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study, physiologic testing, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, psychosocial assessment and care
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Conditions
Type 1 Gaucher Disease
Interventions
AT2101
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Conditions
Plasma Cell Myeloma Refractory
Interventions
SAR446523
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Conditions
Healthy
Interventions
Metformin, Canagliflozin (JNJ-28431754)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Neptune City, New Jersey